Veterinary Biologics Market Overview
The Veterinary Biologics Market is experiencing significant growth, driven by advancements in biotechnology and increased awareness of animal health. In 2025, the market is projected to reach approximately USD 14 billion, with expectations to grow to USD 25.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.3% .
Key drivers of this growth include the rising prevalence of infectious diseases among livestock and companion animals, the expansion of intensive animal farming practices, and the increasing demand for animal-derived food products. Additionally, the global rise in pet ownership has contributed to the surge in demand for veterinary biologics.
Vaccines dominate the market, accounting for over 90% of the share. Innovations such as recombinant DNA technology, vector-based vaccines, and mRNA platforms are enhancing the efficacy and safety of these biologics. Companies are also focusing on developing combination vaccines to reduce the number of injections and improve compliance.
FAQs
Q1: What are veterinary biologics?
A1: Veterinary biologics are biological products, including vaccines and immunostimulants, used to prevent or treat diseases in animals.
Q2: Why is the veterinary biologics market growing?
A2: The market is expanding due to increased demand for animal health solutions, advancements in biotechnology, and rising pet ownership.